Akèy › Limfom Difize Gwo Selil B › Wisconsin › Milwaukee
Etid klinik pou Limfom Difize Gwo Selil B nan Milwaukee, WI
16 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Milwaukee (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 11 mi lwen
- Froedtert and MCW Moorland Reserve Health Center, New Berlin · 11 mi lwen
- ak 3 plis
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- Medical College of Wisconsin ( Site 0103), Milwaukee
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
- Froedtert & Medical College of Wisconsin, Milwaukee
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Ap rekriteFaz 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Medical College of Wisconsin, Milwaukee
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Ap rekriteFaz 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Ap rekriteEtid obsèvasyon
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Medical College of Wisconsin, Milwaukee
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Children's Hospital of Wisconsin, Milwaukee
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Ap rekriteFaz 1/2
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
- Froedtert and MCW Moorland Reserve Health Center, New Berlin · 11 mi lwen
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Ap rekriteEtid obsèvasyon
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Ap rekriteFaz 2
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- ak 4 plis
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Los Angeles, CA17 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Portland, OR15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Nashville, TN14 etid
- Dallas, TX13 etid
- Seattle, WA12 etid
Lòt etid nan Milwaukee
- Kansè (tout kalite)23 etid
- Kansè nan tete23 etid
- Kansè Poumon ki pa ti selil22 etid
- Myelom Miltip21 etid
- Kansè poumon21 etid
- Kansè pwostat20 etid
- Limfòm folikilè19 etid
- Kansè pankreyas18 etid
- Limfòm Non-Hodgkin18 etid
- Kansè ovè17 etid
- Leksemi mieloïd egi17 etid
- Limfòm Burkitt16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.